TMFEBCapital

Todd Campbell

TMFEBCapital’s Activity

Wed Dec 7

NL

Article

EBCapitalMarkets published an article 2:05 PM

Trump Warns Investors "I'm Going To Bring Down Drug Prices"

President-elect Donald Trump took aim at drug developers in a recent Time magazine interview and as a result, biopharma stocks are selling off.

NL

Article

EBCapitalMarkets published an article 10:01 AM

Why Celldex Rallied 22% In November

The aspiring drug developer closed on an acquisition and updated investors on its clinical trial progress last month.

Tue Dec 6

NL

Article

EBCapitalMarkets published an article 11:44 AM

Why Juno Therapeutics Crashed 19.3% in November

A second-halt to a trial of its lead product candidate raises questions over the company's development timeline.

NL

Article

EBCapitalMarkets published an article 11:03 AM

Is This How Juno Therapeutics Gets Back on Track?

Juno Therapeutics' JCAR014 and JCAR017 trial results may offer insight into what's next for the company, now that management has put its JCAR015 program on hold in acute lymphoblastic leukemia.

NL

Article

EBCapitalMarkets published an article 10:22 AM

3 Growth Stocks That Could Double

Fitbit, Ariad Pharmaceuticals, and Trex Company may all be poised to deliver significant returns to investors.

Mon Dec 5

NL

Article

EBCapitalMarkets published an article 3:43 PM

This Marijuana Stock's Sales Are Shrinking: Should We Care?

GW Pharmaceuticals' revenue tumbled in its fiscal fourth quarter, but investors might be better off focusing on the company's future opportunity for sales growth rather than its past.

Sat Dec 3

NL

Article

EBCapitalMarkets published an article 3:22 PM

Rating Marijuana Stocks: Less Risky, More Risky, Most Risky

GW Pharmaceuticals, Aphria Inc., and Insys Therapeutics are all intriguing marijuana stocks, but each of them comes with risks.

NL

Article

EBCapitalMarkets published an article 7:41 AM

Why bluebird bio Shares Rallied 24.7% In November

Following Donald Trump's election and ahead of the release of early-stage data for its multiple myeloma drug bb2121, investor optimism soared.

Fri Dec 2

NL

Article

EBCapitalMarkets published an article 5:41 PM

Why Ariad Pharmaceuticals Soared 47% in November

Post-election optimism that regulators will dial back rhetoric regarding drug prices rekindled investors' interest last month.

NL

Article

EBCapitalMarkets published an article 11:17 AM

Why Celgene Shares Jumped 13.9% In November

A post-presidential election rally ahead of positive interim results released by a collaboration partner helped propel Celgene's shares higher.

NL

Article

EBCapitalMarkets published an article 9:49 AM

Regeneron's CEO Blasts Peers on Innovation

Regeneron CEO Leonard Schleifer thinks that biopharma needs to focus more on innovation and less on pricing for future growth if it wants to restore credibility with payers, patients, and politicians.

Thu Dec 1

NL

Article

EBCapitalMarkets published an article 6:03 PM

The Conversation Is Changing in Washington, and That's Good for Biotech Investors

The 21st Century Cures Act passed the House and is making its way to the Senate. If it becomes law, it could provide drug companies with access to more research dollars and an easier pathway to FDA approval.

CAPS Outperform Pitch

TMFEBCapital wrote about Northwest Pipe Company (NWPX) . 4:18 PM

NWPX Outperform

Drinking and waste water projects are significantly underfunded., According to ASCE, there will be a $84 billion gap between what the U.S. is spending and what should be spent in 2020. Given Trump's desire to improve our water infrastructure and [more]

Caps Pick

TMFEBCapital made a pick in CAPS. 4:18 PM

Northwest Pipe Company (NWPX) will Outperform the S&P 500

CAPS Outperform Pitch

TMFEBCapital wrote about Manitowoc (MTW) . 4:18 PM

MTW Outperform

Top maker of cranes stands to benefit if GDP accelerates because of Trump's infrastructure rebuilding plans. MTW's restructuring provides profit leverage as crane utilization picks up.

Caps Pick

TMFEBCapital made a pick in CAPS. 4:18 PM

Manitowoc (MTW) will Outperform the S&P 500

CAPS Outperform Pitch

TMFEBCapital wrote about Cliffs Natural Resources (CLF) . 4:18 PM

CLF Outperform

biggest maker of iron ore pellets for U.S. steel companies suggests significant earnings potential if Trump's infrastructure plans pass.

Caps Pick

TMFEBCapital made a pick in CAPS. 4:18 PM

Cliffs Natural Resources (CLF) will Outperform the S&P 500
NL

Article

EBCapitalMarkets published an article 4:11 PM

3 Stocks That Could Double Because of President Trump

These infrastructure stocks may be in for better times now that Donald Trump has secured the Oval Office.

NL

Article

EBCapitalMarkets published an article 3:40 PM

A Potentially Astounding Advance in Multiple Myeloma

bluebird bio has released intriguing phase 1 trial data for its novel BCMA targeting CAR-T therapy for multiple myeloma.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 64697 out of 74751
Score -501.47
Score Change Today -35.81
Accuracy 30.00%
Active Picks 47
Total Picks 52
Best Pick MDVN.DL (+145.92)
Worst Pick SFM (-79.66)
Average Score per Pick -9.64
Charms Earned 5
Highest Rated Favorite No Favorites Selected
Go to TMFEBCapital’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show TMFEBCapital’s 10 Latest Posts